Phentermine / Topiramate Oral Product
ApprovedSmall molecule
Phentermine / Topiramate Oral Product is one of 32 small molecule programs targeting Hypothalamic Obesity. It is currently in Approved.
2
Indications
3
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Phentermine / Topiramate Oral Product
SSeattle Children's Hospital
Approved
Byetta
AstraZenecaPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Inderal
WWyeth-Lederle Vaccines
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Sulfonylureas
Eli LillyPreclinical
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Preclinical
Blank Control
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSeattle Children's Hospital